On September 2, 2015, the Patent Trial and Appeal Board (PTAB) declined to institute an inter partes review (IPR) of a patent covering the multiple sclerosis drug Tecfidera®, held by Finnegan client Biogen MA. The IPR petition was filed by the Coalition for Affordable Drugs, a group of hedge funds managed by Kyle Bass.
In its written decision, the PTAB denied the institution on all grounds, stating that the petitioner failed to establish a likelihood that any of the challenged claims were unpatentable. This decision comes just three weeks after Finnegan filed a preliminary response on behalf of Biogen.
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Award/Ranking
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.